Genentech, Inc. (United States) holds 1 active US FDA Type II Drug Master File and 6 inactive and is linked to 7 FDA-registered manufacturing sites. 34 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Genentech, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/genentech-inc

Overview

Genentech, Inc., a biotechnology corporation, is a subsidiary of Roche Holding AG. The company specializes in developing and manufacturing products to treat patients with serious or life-threatening medical conditions, particularly in the areas of oncology, immunology, and neuroscience.

Therapeutic areas

API / Drug Master Files

Genentech, Inc. holds 1 active (7 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • MSBA30K PEG REAGENT FOR MIRCERA (RO0503819)Active2006-06-29
  • CED88004SInactive2017-08-11
  • CED88004AInactive2017-08-11
  • DORNASE ALFA INHALATION SOLUTION (GENENTECH)Inactive1999-11-09
  • THROMBOPOIETIN (HUMAN, RECOMBINANT, CHO CELLS, GENENTECH)Inactive1995-08-21
  • TUMOR NECROSIS FACTOR RECEPTOR IMMUNOGLOBULIN GInactive1993-11-11
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SOUTH SAN FRANCISCO.Inactive1980-11-21

Registered manufacturing sites (7)

Physical sites registered with the US FDA and resolved to Genentech, Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

34 FDA enforcement records linked to this company.

  • recall — Class II2024-06-05

    Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.

  • 4832024-05-02

    Failure to comply with REMS Implementation System

  • 4832024-04-19

    Written procedures not established/followed

  • 4832024-04-19

    Written record of investigation incomplete

  • 4832024-04-19

    Cleaning / Sanitizing / Maintenance

  • 4832024-04-19

    Testing Calculations

  • 4832024-04-19

    Establishment of calibration procedures

  • 4832024-04-19

    Master production and control records, procedure

  • 4832024-04-19

    Scientifically sound laboratory controls

  • recall — Class III2022-11-09

    Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.

  • recall — Class II2021-07-14

    Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

  • recall — Class III2021-05-05

    Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.

  • 4832018-07-05

    Following/documenting laboratory controls

  • 4832018-07-05

    Cleaning SOPs/schedules

  • 4832018-07-05

    Establishment of calibration procedures

  • 4832018-07-05

    Investigations of discrepancies, failures

  • 4832018-07-05

    Procedures for sterile drug products

  • recall — Class III2018-02-21

    Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted from the product carton, primary label is correct.

  • recall — Class I2017-09-27

    Non-Sterility:presence of cracked or chipped glass at the neck of Sterile Water for Injection vials.

  • recall — Class II2017-04-12

    Superpotent Drug: An oversized tablet was found in a bottle.

  • 4832016-07-08

    Authority lacking to review records, investigate errors

  • 4832016-07-08

    Records reviewed annually

  • 4832016-04-15

    Cleaning / Sanitizing / Maintenance

  • 4832016-04-15

    Procedures for sterile drug products

  • recall — Class I2013-01-30

    Presence of Particulate Matter: One lot of Bacteriostatic Water for Injection, USP diluent vials that were packed with Trastuzumab Kits for investigational use has the potential to contain glass particulates.

  • recall — Class III2012-12-26

    Short Fill: some bottles contained less than 120-count per labeled claim.

  • recall — Class II2012-12-12

    Miscalibrated and/or Defective Delivery System: Genentech has received complaints for Nutropin AQ NuSpin 10 & 20 reporting that the dose knob spun slowly and the injection took longer than usual (slow dose delivery).

  • recall — Class II2012-12-12

    Miscalibrated and/or Defective Delivery System: Genentech has received complaints for Nutropin AQ NuSpin 10 & 20 reporting that the dose knob spun slowly and the injection took longer than usual (slow dose delivery).

  • 4832011-06-23

    Aseptic Processing Area

  • 4832011-06-23

    Defined areas of adequate size for operations

  • 4832011-06-23

    Following/documenting laboratory controls

  • 4832011-06-23

    No written record of investigation

  • 4832011-06-23

    Validation lacking for sterile drug products

  • 4832011-06-23

    Written record of investigation incomplete

For suppliers

Is this Genentech, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.